Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Mild COVID-19
Status:
Completed
Trial end date:
2022-05-03
Target enrollment:
Participant gender:
Summary
In this study, we aimed to evaluate the effectiveness and safety of MIR 19 ® in preventing
development of moderate and/or severe course of the disease in mild COVID-19 outpatients.
Primary endpoint:
The proportion of patients with the development of moderate or severe COVID-19 disease (in
accordance with the criteria specified in the Interim Guidelines "Prevention, diagnosis and
treatment of new coronavirus infection (COVID-19)" by the Ministry of Health of the Russian
Federation, version 14 of 27.12.2021 or current at the time of the study) by the 28th day of
observation.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia